Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 13Colorectal Neoplasms 10Carcinoma, Merkel Cell 9Breast Neoplasms 9Carcinoma, Renal Cell 7Neoplasms 6Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 6Small Cell Lung Carcinoma 4Carcinoma, Hepatocellular 4Turcot syndrome 3Stomach Neoplasms 3Neuroendocrine Tumors 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Penile Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Neuroendocrine 2Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 3apatinib 3Magnetic Resonance Spectroscopy 3lenvatinib 2Specimen Handling 2Nivolumab 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1Tretinoin 1Sunitinib 1Radiation 1Pemetrexed 1Nelfinavir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lutetium-177 1Lutetium 1Ipilimumab 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Adenoid Cystic × avelumab × Clear all
NCT03990571 2024-10-18

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 13 charts

Carcinoma, Adenoid Cystic, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡